724.0000 -26.10 (-3.48%)
NSE May 30, 2025 15:31 PM
Volume: 356.2K
 

724.00
-3.48%
KRChoksey
Supriya Life Science reported a quarterly revenue growth of INR 1422.7 mn in Q4FY23, compared to INR 1051.0 mn in Q3FY23. The growth was primarily supported by strong traction in the US, Europe, and Latin America markets. Therapies such as Anti Anesthetic, Anti-Allergic, and Asthmatic played a key role in driving this growth.
Supriya Lifescience .. has an average target of 740.00 from 1 broker.
More from Supriya Lifescience Ltd.
Recommended